Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. 1996

M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
Childhood Cancer Research Group, University of Oxford, U.K.

BACKGROUND Individuals who had cancer in childhood are at higher risk of developing bone cancer than any other type of second primary cancer. OBJECTIVE Using the population-based National Registry of Childhood Tumours in Britain, we investigated the incidence and etiology of second primary bone cancer after childhood cancer in a cohort study and in a case-control study. METHODS A cohort study of 13,175 3-year survivors of childhood cancer diagnosed in Britain between 1940 and 1983 revealed 55 subsequent bone cancers. A largely nested case-control study comprised 59 case subjects developing second primary bone cancer, and 220 control subjects were selected and matched for sex, type of first cancer, age at first cancer, and interval between diagnosis of first cancer and subsequent bone cancer. Outcome measures were the incidence of bone cancer after childhood cancer, the cumulative dose of radiation received at the site of the second cancer in the case subject and at the corresponding anatomic site in the matched control subjects, and the cumulative dose of alkylating agents and vinca alkaloids received by case and control subjects. RESULTS The percentage of 3-year survivors developing bone cancer within 20 years did not exceed 0.9%, except following heritable retinoblastoma (7.2%), Ewing's sarcoma (5.4%), and other malignant bone tumors (2.4%). The risk of bone cancer increased substantially with increased cumulative dose of radiation to the bone (P< .001, linear trend). At the highest levels of exposure, however, the risk appeared to decline somewhat (P=.065, nonlinearity). Exposure to less than 10 Gy was at worst, associated with only a small increased relative risk (RR) of bone cancer (RR= 0.7; 95% confidence interval = 0.2-2.2). The risk of bone cancer increased linearly (P= .04, one-tailed test) with increased cumulative dose of alkylating agents. CONCLUSIONS This population-based study provides grounds for reassurance of the majority of survivors in that their risk of developing bone cancer within 20 years of 3-year survival did not exceed 0.9%. The higher risks found for bone cancer following the other specific rare types of childhood cancer provide a rational basis for surveillance. The RRs reported for bone cancer after specified levels of exposure to radiation should help in making decisions concerning future treatment protocols.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
March 1987, Journal of the National Cancer Institute,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
March 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
June 2015, Human reproduction (Oxford, England),
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
June 1983, The New England journal of medicine,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
July 2011, Radiation protection dosimetry,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
May 2001, Medical and pediatric oncology,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
September 2020, Cancer research,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
March 1962, The Journal of the Tennessee State Medical Association. Tennessee State Medical Association,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
November 2011, Bulletin du cancer,
M M Hawkins, and L M Wilson, and H S Burton, and M H Potok, and D L Winter, and H B Marsden, and M A Stovall
January 1990, Cancer chemotherapy and biological response modifiers,
Copied contents to your clipboard!